Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 10/20 | 0.58 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPA | Q15257 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1438294 | 0.89 | MDM2 (0.63) | MDM2 | |
| SCHEMBL1437004 | 0.89 | MDM2 (0.75) | MDM2 | |
| SCHEMBL1437142 | 0.87 | MDM2 (0.68) | MDM2GABRA2GABRB2ALOX12ALDH1A1 | |
| SCHEMBL9893873 | 0.87 | MDM2 (0.68) | MDM2GABRA2GABRB2ALOX12ALDH1A1 | |
| SCHEMBL9894464 | 0.86 | MDM2 (0.77) | MDM2PTPRCPTPN2PTPN1PTPA | |
| SCHEMBL1437232 | 0.85 | MDM2 (0.61) | MDM2PTPRCPTPN2PTPN1PTPA | |
| SCHEMBL1437371 | 0.85 | MDM2 (0.66) | MDM2PTPRCPTPN2PTPN1PTPA | |
| SCHEMBL1438090 | 0.84 | MDM2 (0.59) | MDM2PTPRCPTPN2PTPN1PTPA | |
| SCHEMBL1437466 | 0.83 | MDM2 (0.58) | MDM2PTPRCPTPN2PTPN1PTPA | |
| SCHEMBL1437209 | 0.83 | MDM2 (0.58) | MDM2GABRA2GABRB2ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470502-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
| WO-2011023677-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885PTPRC 841/4885PTPN2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.